scholarly journals Involvement of Oxidative Stress–Induced DNA Damage, Endoplasmic Reticulum Stress, and Autophagy Deficits in the Decline of β-Cell Mass in Japanese Type 2 Diabetic Patients

Diabetes Care ◽  
2014 ◽  
Vol 37 (7) ◽  
pp. 1966-1974 ◽  
Author(s):  
Hiroki Mizukami ◽  
Kazunori Takahashi ◽  
Wataru Inaba ◽  
Kentaro Tsuboi ◽  
Sho Osonoi ◽  
...  
2011 ◽  
Vol 106 (3) ◽  
pp. 383-389 ◽  
Author(s):  
Pál Brasnyó ◽  
Gergő A. Molnár ◽  
Márton Mohás ◽  
Lajos Markó ◽  
Boglárka Laczy ◽  
...  

Although resveratrol has widely been studied for its potential health benefits, little is known about its metabolic effects in humans. Our aims were to determine whether the polyphenol resveratrol improves insulin sensitivity in type 2 diabetic patients and to gain some insight into the mechanism of its action. After an initial general examination (including blood chemistry), nineteen patients enrolled in the 4-week-long double-blind study were randomly assigned into two groups: a resveratrol group receiving oral 2 × 5 mg resveratrol and a control group receiving placebo. Before and after the second and fourth weeks of the trial, insulin resistance/sensitivity, creatinine-normalised ortho-tyrosine level in urine samples (as a measure of oxidative stress), incretin levels and phosphorylated protein kinase B (pAkt):protein kinase B (Akt) ratio in platelets were assessed and statistically analysed. After the fourth week, resveratrol significantly decreased insulin resistance (homeostasis model of assessment for insulin resistance) and urinary ortho-tyrosine excretion, while it increased the pAkt:Akt ratio in platelets. On the other hand, it had no effect on parameters that relate to β-cell function (i.e. homeostasis model of assessment of β-cell function). The present study shows for the first time that resveratrol improves insulin sensitivity in humans, which might be due to a resveratrol-induced decrease in oxidative stress that leads to a more efficient insulin signalling via the Akt pathway.


2018 ◽  
Vol 120 ◽  
pp. S69
Author(s):  
Noelia Diaz-Morales ◽  
Francesca Iannantuoni ◽  
Irene Escribano-Lopez ◽  
Aranzazu Martinez de Marañon ◽  
Sandra Lopez-Domenech ◽  
...  

2014 ◽  
Vol 21 (12) ◽  
pp. 1759-1765 ◽  
Author(s):  
Susana Rovira-Llopis ◽  
Celia Bañuls ◽  
Nadezda Apostolova ◽  
Carlos Morillas ◽  
Antonio Hernandez-Mijares ◽  
...  

2003 ◽  
Vol 88 (5) ◽  
pp. 2300-2308 ◽  
Author(s):  
Kun Ho Yoon ◽  
Seung Hyun Ko ◽  
Jae Hyoung Cho ◽  
Jung Min Lee ◽  
Yu Bae Ahn ◽  
...  

In the presence of obesity, β-cell mass needs to be increased to compensate for the accompanying demands and maintain euglycemia. However, in Korea, the majority of type 2 diabetic patients are nonobese. We determined the absolute masses, relative volumes, and ratio of α- and β-cell in the pancreas and islets in normal and diabetic Korean subjects to correlate these findings with the clinical characteristics. Whole pancreases procured from organ donors were divided into 24 parts (control 1, n = 9). Tissue was also obtained by surgical resection after 35 partial pancreatectomies: in 25 diabetic patients, 10 age- and body mass index (BMI)-matched patients of benign or malignant pancreatic tumor without diabetes mellitus (DM) (control 2). Morphometric quantifications were performed. In control 1, the relative volume of β-cells was 2.1 ± 0.9%, and the total β-cell mass was 1.3 ± 0.3 g. The relative volume of β-cells was found to be variable (control 1, 2.1 ± 0.9%; control 2, 1.9 ± 0.7%; DM, 1.4 ± 1.0%; P < 0.05 DM vs. control 1 and 2) and showed good correlation with BMI (control 1, r2 = 0.64; DM, r2 = 0.55; all subjects, r2 = 0.38; P < 0.05). Notably, in type 2 diabetic patients, the ratio of α-cell area to β-cell area in the islet was higher than in control 1 and 2 (0.81 ± 0.4 vs. 0.29 ± 0.2, 0.20 ± 0.1, P < 0.05). Additionally, significant α-cell expansion and a decreased β-cell fraction were predominantly observed in larger islets (islet area, >6415 μm2; P < 0.05) in control 1 and diabetic patients. The relative volume of β-cell was found to be correlated with BMI in diabetic patients and normal organ donors. Moreover, decreased β-cell but increased α-cell proportion in the islets suggests for a selective β-cell loss in the pathogenesis of Korean type 2 diabetes.


2012 ◽  
Vol 287 (46) ◽  
pp. 38482-38494 ◽  
Author(s):  
Amy E. Riek ◽  
Jisu Oh ◽  
Jennifer E. Sprague ◽  
Alexandra Timpson ◽  
Lisa de las Fuentes ◽  
...  

2016 ◽  
Vol 22 (18) ◽  
pp. 2650-2656 ◽  
Author(s):  
Noelia Diaz-Morales ◽  
Susana Rovira-Llopis ◽  
Irene Escribano-Lopez ◽  
Celia Bañuls ◽  
Sandra Lopez-Domenech ◽  
...  

Diabetes Care ◽  
2012 ◽  
Vol 35 (10) ◽  
pp. 1981-1985 ◽  
Author(s):  
M. S. Miraghajani ◽  
A. Esmaillzadeh ◽  
M. M. Najafabadi ◽  
M. Mirlohi ◽  
L. Azadbakht

2020 ◽  
Vol 7 (2) ◽  
Author(s):  
Najah RH ◽  
Mohammad AAH ◽  
Ammar RMR

Introduction: Evidence has long existed regarding the relationship between oxidative stress and diabetes. The present study was conducted to assess the effect of atorvastatin on selected oxidative stress parameters in the form of reduced glutathione (GSH), lipid peroxidation byproduct malondialdehyde (MDA) levels, glutathione –S- transferase (GST) activity and catalase (CAT) activity) and its effect on lipid profile (total cholesterol (TC), triglyceride (TG), high density lipoprotein (HDL), low density lipoprotein (LDL) and very low density lipoprotein (VLDL) in dyslipidaemic type 2 diabetic patients . Materials and Methods: Fifty nine dyslipidaemic type 2 diabetic patients were included in this study. Full history was taken and general examination of patients was performed. Patients studied were taking glibenclamide (an oral hypoglycaemic drug) during the study as a treatment for their disease. These patients were followed up for 60 days and divided randomly into 2 groups. Group I (n = 31): no drug was given and served as dyslipidaemic diabetic control. Group II (n = 28): received atorvastatin tablets 20 mg once daily at night. Of the 59 Fifty patients, 46 completed the study while 13 patients withdrew. This is due to non compliance of the patients. Blood samples were drawn from the patients at the beginning and after 60 days of follow up between 8:30 & 10:30 am after at least 12-14 hours fast. Fasting blood glucose, lipid profile, selected oxidative stress parameters (GSH, MDA levels, GST and CAT activities) were measured. Renal and hepatic functions were also assessed. Results: This study revealed that: atorvastatin treatment increased serum GSH; reduced MDA levels significantly while did not significantly affect CAT and GST activity. In atorvastatin treatment, TC, TG, LDL and VLDL decreased significantly while HDL increased significantly. Conclusion: There was insignificant correlations between atorvastatin induced changes in the oxidation markers and the observed changes of the lipid profile.


Sign in / Sign up

Export Citation Format

Share Document